PharmAthene to Present at the 2011 Chemical and Biological Defense Science and Technology Conference

ANNAPOLIS, Md., Nov. 16, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP) announced today that data from its rPA anthrax vaccine and chemical nerve agent bioscavenger programs will be presented at the 2011 Chemical and Biological Defense Science and Technology (CBD S&T) Conference, being held in Las Vegas, NV, November 14-18, 2011.

"The CBD S&T annual conference is one of the leading biodefense industry meetings and it is an honor to present among the best, new, dynamic developments in basic and applied research within the chemical and biological defense landscape," commented Dr. Thomas Fuerst, Executive Vice President and Chief Scientific Officer.  "We are pleased to offer attendees the opportunity to explore the advancements made in our rPA anthrax vaccine and bioscavenger programs."

A poster titled, "Stability Characterization of an rPA Anthrax Vaccine" will be presented by Dr. Parveen Kaushal, Director of Analytical Sciences for PharmAthene, on Wednesday, November 16, 2011 between 6:00 and 8:00 p.m., P.S.T.

In addition, Dr. John Troyer, Vice President, Chemical Defense Product Development for PharmAthene, presented a poster titled, "A Single Dose Pharmacokinetic Comparison of Recombinant Butyrylcholinesterase (rBChE) Alone or in Combination with Recombinant Human Hyaluronidase (rHuPH20) in the Minipig Model," on Tuesday, November 15, 2011, between 6:00 and 8:00 p.m., P.S.T.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

SparVax™ - a second generation recombinant protective antigen (rPA) anthrax vaccine
Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
Recombinant BChE- a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents


In addition, pursuant to an opinion issued September 22, 2011 from the Delaware Court of Chancery, PharmAthene is entitled to 50% of the net profits over 10 years from all sales of SIGA Technologies' ST-246, a novel smallpox antiviral agent being developed by SIGA for the treatment and prevention of morbidity and mortality associated with exposure to the causative agent of smallpox, and related products, once SIGA receives the first $40 million in net profits from sales of ST-246. 

For more information about PharmAthene, please visit www.PharmAthene.com.

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; "will"; "project"; "potential"; or similar statements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements other than as required by law. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, challenges related to the implementation of our NYSE Amex compliance plan, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC").  Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at www.PharmAthene.com.

SOURCE PharmAthene, Inc.

 
CONTACT: Stacey Jurchison, PharmAthene, Inc., +1-410-269-2610, Stacey.Jurchison@PharmAthene.com

Web Site: http://www.pharmathene.com

 
 
 

Posted: November 2011

View comments

Hide
(web1)